指南与共识流行病学与生物统计医学教育与科研方法

亚临床甲状腺功能减退症的甲状腺激素治疗:临床实践指南

Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline.
指南 / 共识 · BMJ · 2019-05-14

本指南由包括患者、临床医生和方法学家的小组采用GRADE方法制定,针对成人亚临床甲状腺功能减退症(SCH)。基于21项试验共2192名参与者的系统评价,指南强烈推荐不对SCH成人使用甲状腺激素,但该推荐不适用于备孕女性或TSH>20 mIU/L的患者,可能不适用于严重症状或年轻成人(如≤30岁)。

要点

  • 对于SCH成人(TSH升高、游离T4正常),强烈推荐不使用甲状腺激素。
  • 该推荐不适用于备孕女性或TSH>20 mIU/L的患者。
  • 该推荐可能不适用于严重症状或年轻成人(如≤30岁)。

核心结论

  • 指南小组强烈推荐不对亚临床甲状腺功能减退症成人使用甲状腺激素。
  • 该推荐不适用于备孕女性或TSH>20 mIU/L的患者,可能不适用于严重症状或年轻成人(如≤30岁)。

研究设计与样本

  • 指南小组包括患者、临床医生和方法学家,遵循可信赖指南标准,采用GRADE方法制定推荐。
  • 证据基于一项系统评价,纳入21项试验共2192名参与者。

主要发现

  • 对于SCH成人,甲状腺激素在生活质量或甲状腺相关症状(包括抑郁症状、疲劳和体重指数)方面一致显示无临床相关获益(中至高质量证据)。
  • 甲状腺激素对心血管事件或死亡率可能几乎没有或没有影响(低质量证据),但危害仅在一项试验中测量,该试验两年随访期间事件很少。

关键数值与推荐

  • 推荐强度:强烈推荐不使用甲状腺激素(针对SCH成人,TSH升高且游离T4正常)。
  • 推荐不适用于:备孕女性或TSH>20 mIU/L的患者。
  • 推荐可能不适用于:严重症状或年轻成人(如≤30岁)。

临床怎么用

  • 临床医生应监测这些成人甲状腺功能异常的进展或缓解。
  • 通过MAGIC平台的多层证据摘要和决策辅助工具提供相对和绝对获益与危害,以支持共享决策和指南改编。

局限性

  • 危害仅在一项试验中测量,该试验两年随访期间事件很少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CLINICAL QUESTION: What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice. CURRENT PRACTICE: Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels >10 mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing. RECOMMENDATION: The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH >20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old). HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, clinicians, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach. THE EVIDENCE: The systematic review included 21 trials with 2192 participants. For adults with SCH, thyroid hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid related symptoms, including depressive symptoms, fatigue, and body mass index (moderate to high quality evidence). Thyroid hormones may have little or no effect on cardiovascular events or mortality (low quality evidence), but harms were measured in only one trial with few events at two years' follow-up. UNDERSTANDING THE RECOMMENDATION: The panel concluded that almost all adults with SCH would not benefit from treatment with thyroid hormones. Other factors in the strong recommendation include the burden of lifelong management and uncertainty on potential harms. Instead, clinicians should monitor the progression or resolution of the thyroid dysfunction in these adults. Recommendations are made actionable for clinicians and their patients through visual overviews. These provide the relative and absolute benefits and harms of thyroid hormones in multilayered evidence summaries and decision aids available in MAGIC (https://app.magicapp.org/) to support shared decisions and adaptation of this guideline.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019. PMID: 31088853. doi:10.1136/bmj.l2006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。